Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Short Interest Down 38.3% in April

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totaling 36,638 shares, a drop of 38.3% from the April 15th total of 59,393 shares. Based on an average daily volume of 97,175 shares, the short-interest ratio is currently 0.4 days. Currently, 1.4% of the shares of the stock are short sold.

Cyclacel Pharmaceuticals Stock Up 0.2%

Shares of Cyclacel Pharmaceuticals stock traded up $0.00 during trading hours on Monday, reaching $1.00. The company’s stock had a trading volume of 5,359 shares, compared to its average volume of 98,652. Cyclacel Pharmaceuticals has a one year low of $0.73 and a one year high of $32.25. The stock has a market cap of $5.51 million, a P/E ratio of -0.22 and a beta of -0.49. The business has a fifty day simple moving average of $0.99.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cyclacel Pharmaceuticals presently has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.